• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Cost Savings More Important for Payer Committees than Clinical Concerns

Article

Pharmacy and therapeutic committees view potential cost savings as the most important factor when recommending formulary placement, according to a new survey.

With rising prescription drug prices challenging payers, how are their key decision makers adjusting their approach to recommending coverage for medicines?

A new survey finds that pharmacy and therapeutic committees, whose job it is to assess the clinical effectiveness of new drugs, view potential cost savings as the most important factor when recommending formulary placement. A formulary is a list of drugs that receive preferred coverage.

On a scale of one to six, potential cost savings of a drug ranked highest, at 3.8. This priority edged out the overall safety and efficacy of a drug relative to directly comparable medicines, at 3.7, according to the survey of P&T committees conducted by Barclays Bank analysts.

Read more at The Wall Street Journal: http://on.wsj.com/1H1vYkb

Related Videos
Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions
dr kimberly maxfield
Amal Trivedi, MD
Ted Okon, MBA, Community Oncology Alliance
Lalan Wilfongd, MD, US Oncology Network
Allister Chang, co-founder, Fabric Health
Mike Koroscik, MBA, MHA, vice president of oncology, Allina Health and the Allina Health Cancer Institute
Margaret Liang, MD, MSHPM, gynecologic oncologist and health services researcher, program director for the gynecologic oncology fellowship program, Cedars-Sinai Medical Center, Cedars-Sinai Cancer Center
Kathy Oubre, MS, CEO, Pontchartrain Cancer Center
Jennifer Sturgill, DO, Central Ohio Primary Care
Related Content
© 2023 MJH Life Sciences
AJMC®
All rights reserved.